Document and Entity Information - USD ($) $ in Billions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Feb. 19, 2025 |
Jun. 28, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | APLS | ||
| Entity Registrant Name | APELLIS PHARMACEUTICALS, INC. | ||
| Entity Central Index Key | 0001492422 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Large Accelerated Filer | ||
| Entity Small Business | false | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Common Stock, Shares Outstanding | 125,515,813 | ||
| Entity Well-known Seasoned Issuer | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Public Float | $ 4.2 | ||
| Entity Current Reporting Status | Yes | ||
| Entity File Number | 001-38276 | ||
| Entity Tax Identification Number | 27-1537290 | ||
| Entity Address, Address Line One | 100 Fifth Avenue | ||
| Entity Address, City or Town | Waltham | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02451 | ||
| City Area Code | 617 | ||
| Local Phone Number | 977-5700 | ||
| Entity Interactive Data Current | Yes | ||
| Security 12b Title | Common Stock, $0.0001 par value per share | ||
| Security Exchange Name | NASDAQ | ||
| Entity Incorporation, State or Country Code | DE | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Financial Statement Error Correction | false | ||
| ICFR Auditor Attestation Flag | true | ||
| Auditor Name | Deloitte & Touche LLP | ||
| Auditor Firm ID | 34 | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Apellis Pharmaceuticals, Inc. and subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2025, expressed an unqualified opinion on the Company’s internal control over financial reporting. |
||
| Documents Incorporated by Reference | The registrant intends to file a definitive proxy statement pursuant to Regulation 14A in connection with its 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2024. Portions of such proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K. |